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About a fourth of the human proteome is anchored by transmembrane helices (TMHs) to 
lipid membranes. TMHs require multiple hydrophobic residues for spanning membranes, 
and this shows a striking resemblance with the requirements for peptide binding to 
major histocompatibility complex (MHC) class I. It, therefore, comes as no surprise that 
bioinformatics analysis predicts an over-representation of TMHs among strong MHC 
class I (MHC-I) binders. Published peptide elution studies confirm that TMHs are indeed 
presented by MHC-I. This raises the question how membrane proteins are processed 
for MHC-I (cross-)presentation, with current research focusing on soluble antigens. The 
presentation of membrane-buried peptides is likely important in health and disease, as 
TMHs are considerably conserved and their presentation might prevent escape muta-
tions by pathogens. Therefore, it could contribute to the disease correlations described 
for many human leukocyte antigen haplotypes.
Keywords: antigen presentation, antigen cross-presentation, membrane proteins, bioinformatics, adaptive 
immunity, transmembrane domain, epitopes, t lymphocyte
Human leukocyte antigen (HLA) molecules play a vital role in the immunological T cell response. 
HLA-A and HLA-B code for major histocompatibility complex (MHC) class I, which mainly pre-
sents peptide fragments derived by proteasomal degradation of “self ” proteins on the cell surface of 
the antigen presenting cell to cytolytic T cells (1–3). HLA encoding genes are highly polymorphic 
and over 8,500 unique HLA-A and HLA-B haplotypes have been identified to date (4, 5), each 
presenting different peptide fragments of mostly nine amino acids in length (6). This polymor-
phism provides an evolutionary advantage, because pathogens cannot easily develop resistance by 
mutating residues critical for binding to all HLA haplotypes. In this article, we reason that another 
way how resistance is prevented is by the presentation of stretches of amino acids which are critical 
for protein function: those located within transmembrane helices (TMHs) of integral membrane 
proteins.
Each HLA-A and HLA-B haplotype presents peptides with preferential requirements for the 
charge and hydrophobicity of each residue within the peptide (7). Based on these requirements for 
HLA binding, the haplotypes of HLA-A and HLA-B can be grouped in five and seven super types, 
respectively (7–10). The binding peptides (binders) for these super types can be predicted from 
protein sequences by bioinformatics tools (11, 12), whose high accuracy was empirically confirmed 
in several studies (13–16). For most HLA-A and HLA-B super types, the presence of multiple hydro-
phobic residues is favorable for peptide binding (7).
Figure 1 | Transmembrane-derived peptides are preferentially bound by major histocompatibility complex (MHC) class I haplotypes due to their hydrophobic 
nature. (a) Epitopes derived from transmembrane helices (TMHs) are over-presented by all human leukocyte antigen (HLA)-A and most HLA-B super types.  
The bar graphs show the percentages of predicted binders for all HLA-A and HLA-B super types from the human proteome overlapping with predicted TMHs  
by at least one residue. Predictions of MHC class I-binding peptides of nine amino acids in length from the human proteome were made using the stabilized matrix 
method. These were compared with all TMHs predicted by TMHMM version 2.0 (23). The red lines show the 99.9% confidence interval of overlapping binders 
based on random distribution over the proteome. (B) Hydrophobicity distribution of all peptides in the human proteome (black curve) compared to peptides 
overlapping with TMHs (red curve). (C) Percentage of peptides overlapping with TMHs per decile of hydrophobicity. (d) Percentage of TMH-overlapping  
predicted binders versus hydrophobic preference score for each individual haplotype.
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The occurrence of multiple hydrophobic residues in close 
proximity of each other is a hallmark of TMHs. Due to the 
hydrophobic nature of lipid membranes, a transmembrane motif 
of mostly 23 amino acids in length containing non-polar head-
groups is required to span the membrane (17). These stretches 
are frequently flanked by bulky hydrophobic residues, such as 
tryptophan, that allow for anchoring of the protein at the water–
lipid interface, and by positively charged lysine and arginine 
residues that allow for electrostatic interactions with negatively 
charged lipid headgroups (18–20). Similar to HLA binders, the 
presence of TMHs can be predicted with high accuracy from 
protein sequences (21). Approximately 25% of all human genes 
code for integral membrane proteins that are anchored by one or 
more TMHs to the plasma membrane or to the lipid membranes 
of organelles.
Since both HLA-A/B binders and TMHs contain multiple 
hydrophobic residues, it is likely that HLA-A and HLA-B haplo-
types would preferentially present peptides derived from TMHs. 
This is supported by a comparison of the predicted binders 
with predicted TMHs from the human proteome (Figure 1A). 
Figure 2 | The major histocompatibility complex class I binding preference of transmembrane helix (TMH)-derived peptides is mainly attributable to their large 
hydrophobicity. Based on the hydrophobicity distribution of the peptides overlapping with TMHs, a control set of peptides was generated with a similar 
hydrophobicity distribution but now derived from soluble protein regions (i.e., non-TMHs). (a) Predicted hydrophobicity distribution of all peptides in the human 
proteome (black curve), peptides overlapping with TMHs (red curve), and the control set from soluble protein regions (green curve). Note the almost complete 
overlap of the red and green curves. (B) Percentages of predicted binders from the control set of soluble protein regions versus the percentage of predicted  
binders from TMHs (Figure 1a) for each human leukocyte antigen (HLA)-A and HLA-B super type. The black line shows the expected relationship if there  
were no differences between the two sets except their sizes (note that the control set is only 1/10 of the number of peptides derived from TMHs, resulting in  
lower percentages; see Methods).
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Predicted TMHs contain more predicted HLA binders than 
expected from a random distribution of binders for all HLA-A 
and most HLA-B super types, and this was significant for all HLA 
super types (see Methods; P < 0.001; individual P values in Table 
S1 in Supplementary Material). Comparing the hydrophobicity 
(22) of all peptides in the human proteome reveals that peptides 
derived from TMHs are more hydrophobic than those originat-
ing from other protein regions (Figure 1B) and more than 90% 
of the 10% most hydrophobic peptides originate from TMHs 
(Figure 1C).
We performed two control analyses to determine to what extent 
the preferential HLA binding of TMH-derived peptides was 
related to their hydrophobicity. First, we scored the hydrophobic 
preference for each HLA super type (see Methods). Haplotypes 
for which this score is positive will bind peptides with above 
average hydrophobicity. We found a strong correlation (r = 0.88) 
between these hydrophobic preference scores and the percent-
ages of predicted HLA-binding peptides derived from TMHs 
(Figure 1D). For a second control, we selected a set of peptides 
derived from non-transmembrane protein regions of the human 
proteome, but with a matching hydrophobicity distribution as of 
those derived from TMHs (Figure 2A). If the predicted prefer-
ential presentation of peptides locating to TMHs were entirely 
attributable to their large hydrophobicity, we would expect these 
control peptides to be equally well presented. Indeed, this was 
largely the case (Figure 2B), except for HLA-A02. For HLA-A02, 
peptides derived from TMHs were predicted to be presented with 
a lower probability than peptides from the control set. Possibly 
this may be due to the specific compositional requirements of 
TMHs resulting in less-favorable positioning of residues as in 
other hydrophobic domains critical for HLA-A02 binding.
To investigate this compositional bias further, we also deter-
mined the positions of the predicted binders relative to the posi-
tions of the predicted TMHs (Figure 3). These positions seem to 
correlate well with the requirements for peptide binding to the 
different HLA haplotypes. For instance, predicted binders of the 
HLA-A02 super type are mainly located within the hydropho-
bic core of TMHs, which is consistent with the requirement of 
multiple hydrophobic amino acids within the peptides (7). In 
contrast, binders for the HLA-B27 super type are enriched at the 
lipid–water interface of TMHs, correlating to its preference for 
charged amino acids within the epitope (7).
A survey of the literature confirmed that membrane-buried 
peptides are presented in MHC-I. Comparison of the predicted 
TMHs with the MHC-I epitopes identified from B lympho blastoid 
cell lines by peptide elution coupled to mass spectrometry, revealed 
that approximately 1% of naturally presented MHC-I epitopes are 
predicted to be located within TMHs (24). The hydrophobicity of 
these detected epitopes is somewhat lower than of the predicted 
binders (compare Figure 4A with Figure 1B), and approximately 
15% of the 10% most hydrophobic detected epitopes is derived 
from TMHs (Figure 4B). This percentage is lower than one would 
expect purely based on the predicted binding affinity (Figure 1C), 
which might be due to a lower abundancy of transmembrane pro-
teins compared to soluble proteins. Alternatively or additionally, 
the lower percentage of peptides derived from TMHs might be 
caused by a lower detection efficiency, as hydrophobic peptides 
are often underrepresented in mass spectrometry due to their 
Figure 4 | Analysis of peptide elution studies reveals major histocompatibility complex class I presentation of epitopes derived from transmembrane helices 
(TMHs). Peptides eluted from B lymphoblastoid cell lines and detected by mass spectrometry (24) were analyzed for their hydrophobicity and overlap with TMHs.  
(a) Hydrophobicity index distribution of all eluted epitopes (black curve) compared to epitopes derived from TMHs (red curve). (B) Percentage of detected epitopes 
derived from TMHs per decile of hydrophobicity.
Figure 3 | All human leukocyte antigen-A and B super types preferentially 
present specific sections of TMHs. The histograms show the distribution of 
the middle positions of all predicted major histocompatibility complex class 
I-binding 9-mers relative to the middle position of the nearest predicted TMH 
of 23 residues in length. The position of the TMH is indicated by the yellow 
shaded bar.
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poor solubilization and ionization characteristics (25, 26). In any 
case, this survey of peptide elution studies (24) shows that MHC-I 
presents epitopes derived from TMHs.
In fact, many known MHC-I-binding epitopes locate within 
transmembrane helices. For HLA-A02, which is the most 
prevalent HLA-A haplotype in the Caucasian population (27), 
more than 10% of the epitopes in the Immune Epitope Database 
(28) correspond to peptide fragments overlapping with TMHs. 
These include many well-studied and clinically important 
epitopes that were found in in vivo studies. For example, mul-
tiple HLA-A02-binding epitopes are derived from the TMH of 
the viral coat protein gp41 from the human immunodeficiency 
virus (29). The same holds true for cancer recognition, and for 
instance an HLA-A02-binding epitope derived from the TMH of 
melanoma antigen recognized by T-cells 1 (Mart1; also known as 
Melan-A; residues 26–35) (30) is strikingly immunodominant, 
with few other MHC-I epitopes described (31).
The presentation of epitopes derived from TMHs could offer 
a clear evolutionary advantage. TMHs are well-conserved as 
there are strict compositional requirements for spanning lipid 
membranes (17). In addition to a hydrophobic core, the charge 
distribution of adjacent residues is a critical determinant for the 
orientation of a TMH within the membrane (32). The length 
of TMHs is important for the localization of transmembrane 
proteins to the correct organellar membrane (33). Because the 
precise composition of TMHs is essential for protein confor-
mation and localization, pathogens might be unable to evade 
antigen presentation by mutating these regions. We believe this 
could constitute a novel mechanism contributing to the fidelity 
of antigen presentation.
It is mechanistically unclear how TMHs can be processed 
for MHC-I antigen presentation. For presentation of self-coded 
antigens in MHC-I, membrane proteins need to be first extracted 
from the membrane and subsequently targeted to the proteasome 
for the generation of antigenic epitopes (Figure 5). To date, this 
extraction has only been described for transmembrane proteins 
in the endoplasmic reticulum (ER) by a process that involves 
the ER-associated degradation pathway. This incompletely 
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Figure 5 | Current models cannot explain presentation of epitopes derived from endogenous and exogenous membrane proteins. Left: scheme of major 
histocompatibility complex (MHC) class I (MHC-I) presentation of membrane-buried epitopes derived from endogenous membrane proteins. (1) ER-resident 
membrane proteins can be degraded after extraction from the membrane by an ER-associated degradation-dependent mechanism and subsequently degraded  
by the proteasome. (2) Membrane proteins locating at other organelles can be targeted to intraluminal vesicles of multi-vesicular bodies (MVB) by the ESCRT 
machinery. After fusion of the MVBs with lysosomes, these vesicles (including the transmembrane proteins) are degraded by lysosomal enzymes. If and how these 
pathways contribute to MHC class I (MHC-I) presentation is unclear. Right: scheme of cross-presentation of membrane-buried epitopes derived from exogenous 
proteins. (3) Membrane structures (e.g., apoptotic bodies, microbial pathogens) are internalized by endocytosis or phagocytosis. The endosomes or phagosomes 
containing the membrane-buried epitopes fuse with lysosomes resulting in degradation of the membrane proteins. How these membrane-buried epitopes can be 
extracted from the membrane and loaded onto MHC-I is unknown.
understood process is predominantly being studied in yeast (34, 
35) and it is unclear if and to what extent it contributes to antigen 
presentation in mammals. However, self-presentation of an 
epitope derived from the TMH of Mart1 is dramatically enhanced 
with a mutant form that is selectively retained at the ER (36), sug-
gesting that extraction of proteins from the ER membrane may 
well be of major importance for antigen presentation. Further 
evidence that TMH-derived epitopes are generated at the ER 
comes from the finding that a peptide fragment from the TMH 
of Mart1 is trimmed by the ER-associated proteases (ERAP) to 
release the MHC-I epitope (37).
The processing of TMHs for MHC-I presentation may well 
be mechanistically reminiscent to HLA-E presentation. HLA-E 
is a paralog of MHC-I specialized in the presentation of epitopes 
derived from the N-terminal signal peptides of other MHC-I 
paralogs, including HLA-A and HLA-B, for recognition by 
natural killer cells (38). These signal peptides resemble TMHs 
and are extracted from the ER membrane following cleavage by 
the signal peptide peptidase (39), and subsequently processed by 
the proteasome for HLA-E presentation (40). In this respect, it is 
interesting that downregulation of ERAP1 leads to upregulation 
of HLA-E, suggesting a functional link between HLA-E presenta-
tion and conventional antigen presentation (41).
It is also unclear whether and via which mechanisms trans-
membrane proteins locating at other organelles (i.e., outside the 
ER) are processed for MHC-I presentation. These trans membrane 
proteins are degraded in lysosomes via the formation of multi-
vesicular bodies (Figure 5) (42). If and how these mechanisms 
contribute to the release of epitopes from TMHs for MHC-I 
presentation is yet unknown.
How integral membrane proteins can be processed for antigen 
cross-presentation is unclear as well. Cross-presentation is the 
process by which antigen presenting cells take up, process, and 
eventually present extracellular antigen on MHC-I to cytolytic 
T  lymphocytes. There are currently two mechanistic pathways 
of antigen cross-presentation described (43), but for both 
pathways it is not easy to envision how they could result in cross-
presentation of transmembrane proteins (Figure 5). In the first 
6Bianchi et al. Antigen Presentation of Membrane Proteins
Frontiers in Immunology | www.frontiersin.org September 2017 | Volume 8 | Article 1118
cytosolic pathway, ingested proteins translocate from endosomes 
into the cytosol where they become accessible for proteasomal 
degradation. The proteasome-derived peptides can then be 
imported into the ER or back into endosomes for subsequent 
loading onto MHC-I. The processing of transmembrane proteins 
would require either (i) the extraction of the TMHs from the lipid 
membrane within the lumen of endosomes or (ii) the transloca-
tion of large membrane fragments incorporating the antigen. 
In the second vacuolar pathway, proteins are degraded within 
endosomes by lysosomal proteases and subsequently loaded 
onto MHC-I. For processing of transmembrane proteins via this 
pathway, the TMHs need to be also extracted from the membrane 
or (iii) cleaved within the lipid membrane. All these processes 
have not been described to date.
Thus, from emerging bioinformatics information, the concept 
arises that most HLA-A and HLA-B haplotypes are biased to 
present epitopes derived from TMHs. Our present knowledge of 
antigen presentation is exclusively based on that of soluble anti-
gens, and we currently cannot explain how antigen presenting 
cells can self- and cross-present integral membrane proteins. Both 
these processes can be expected to require unique, yet unknown, 
mechanisms and this might well relate to the disease-associations 
of specific HLA haplotypes. For instance, members of the HLA-
B27 super type are associated with spondyloarthropathies (pso-
riasis, inflammatory bowel disease, reactive arthritis, ankylosing 
spondylitis) (44). As we explained in this Opinion article, this 
super type preferentially presents epitopes that are immediately 
adjacent to transmembrane helices and perhaps medullary 
thymic epithelial cells cannot efficiently present these peptide 
fragments. This would result in incomplete negative selection 
and a population of self-reactive cytolytic T cells, which might 
contribute to the pathology of these inflammatory diseases. 
Evidence for such an incomplete self-tolerance of membrane-
buried epitopes comes from the finding that a large proportion of 
healthy HLA-A02 restricted individuals possess naive cytolytic 
T cells specific for the immunodominant epitope from the TMH 
of Mart1 (45). Resolving how TMHs are processed for antigen 
self-presentation and cross-presentation should allow for a better 
understanding of immunology, and it might ultimately allow for 
new insights into the mechanisms of the disease-associations of 
HLA haplotypes.
MetHods
input data
The UniProt human reference proteome UP000005640_9606 was 
used for all analyses.
In Silico predictions
Transmembrane helices for all human proteins were predicted 
using the TMHMM Server 2.01 (23). HLA-binding 9-mers were 
predicted using a custom R implementation2 of the SMMPMBEC 
1 http://www.cbs.dtu.dk/services/TMHMM/.
2 https://github.com/jtextor/epitope-prediction.
method (46). For each HLA super type, IC50 values for all 9-mers 
from the human proteome were predicted. The 2% peptides with 
the lowest IC50 values were defined as binders.
overlap analysis
Of all 9-mers in the human proteome, 5.3% are predicted to 
overlap with TMHs (TMHs) by at least one amino acid (i.e., 
based on the sequence coverage of TMHs on the entire human 
proteome). Therefore, if there were no correlation between TMH 
overlap and HLA binding, the share of TMH peptides among 
predicted HLA binders would equally be 5.3%. As a statistical test 
of this null hypothesis, we used the binomial test. Specifically, the 
null hypothesis of this binomial test is that every predicted HLA 
binder is independently chosen at random to be TMH overlap-
ping with probability 0.053. Confidence intervals for repeated 
sampling under this null hypothesis were determined from the 
critical region of this binomial test, for which we chose an alpha 
value of 0.001 (R code provided as Supplemental Information). 
Note that the independence assumption of the binomial test is 
approximate in this case, but because the predicted HLA binders 
constitute only 2% of the 9-mers in the human proteome, this 
approximation is reasonable.
Hydrophobicity index
Kyte–Doolittle scores were used to describe hydrophobicity of 
amino acids (22). The hydrophobicity of a peptide was calculated 
as the mean hydrophobicity of its constituting amino acids. 
Hydrophobicity indices for each HLA allele were calculated by 
multiplying the height of each amino acid in the binding motif 
with the Kyte–Doolittle score of the corresponding amino acid 
and averaging these values for all combinations of positions and 
amino acids. The mean hydrophobicity index of peptide in the 
human proteome was then subtracted for normalization. Binding 
motifs for this purpose were derived from the SMMPMBEC 
matrix M as explained in the Supporting Information.
Control set of Hydrophobic epitopes  
from soluble protein regions
To construct a control set of peptides derived from soluble protein 
regions (i.e., non-TMHs) with a similar hydrophobicity distribu-
tion as the peptides overlapping with TMHs, we determined each 
percentile of the TMH peptide hydrophobicity distribution and 
sampled equal amounts of soluble protein peptides within each 
percentile. Since by far most hydrophobic peptides overlap with 
TMHs (Figure 1C), we could only obtain a control set with a size 
1/10 of the TMH peptide set.
reproducibility
The R scripts used to perform the analyses shown in this paper 
are available as Supplemental Material.
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